BUSINESS WATCH

摘要

A generation of drugs with the potential to cure hepatitis C is set to flood the market. This month, Vertex Pharmaceuticals, based in Cambridge, Massachusetts, and drug behemoth Merck, headquartered in Whitehouse Station, New Jersey, both released promising results from late-stage clinical trials of their leading drugs against the hepatitis C virus (HCV).